News | June 02, 2025
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
More than 40 types of Amyloid proteins are discovered till date
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
PRX-PLUS has a unique product feature with its deep-impacting formula
The freshly infused capital will primarily be deployed towards expansion and research & development
First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love
Subscribe To Our Newsletter & Stay Updated
